JPRN-UMIN000053195招募中2 期
A phase II clinical trial of neoadjuvant gemcitabine and S-1 with concurrent radiotherapy in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma - A phase II clinical trial of neoadjuvant gemcitabine and S-1 with concurrent radiotherapy in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma
Department of Gastroenterological Surgery, Faculty of Medicine, Kagawa University0 个研究点目标入组 64 人开始时间: 2023年12月22日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 64
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 86years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients with pulmonary fibrosis or interstitial pneumonia 2) Patients with other active cancers 3) Patients who can not take medicine orally 4) Patients with severe allergies 5) Patients with watery diarrhea 6) Patients with severe co-morbid disease 7) Patients seems inadequate for this study by investigator(s)
研究者
相似试验
招募中
2 期
A phase II clinical trial of neoadjuvant gemcitabine and S-1 with concurrent hypofractionated radiotherapy in patients with resectable and borderline resectable pancreatic ductal adenocarcinomaresectable and borderline resectable (BR-PV) pancreatic cancerJPRN-UMIN000038585Department of Gastroenterological Surgery, Faculty of Medicine, Kagawa University54
招募中
2 期
Randomized phase II trial of neoadjuvant Gemcitabine/S-1 based chemoradiotherapy for potentially resectable pancreatic ductal adenocarcinomainvasive pancreatic ductal adenocarcinomainvasive pancreatic ductal adenocarcinoma, potentially resectable pancreatic cancerJPRN-jRCTs041200079Mizuno Shugo70
已完成
不适用
Phase I/II trial of neoadjuvant intravenous gemcitabine plus intra-arterial cisplatin in muscle-invasive bladder cancer.bladder cancerJPRN-UMIN000013636ippon Medical School Musashokosugi Hospital20
进行中（未招募）
不适用
Efficacy and safety of immune checkpoint inhibitor in localized biliary tract cancerNeoplasmsKCT0004415Asan Medical Center45
已完成
2 期
Gemcitabine, Oxaliplatin and Radiotherapy in Treating Patients With Completely Resected Pancreatic CancerPancreatic NeoplasmsNCT00191568Eli Lilly and Company45